The Effectiveness of Intravitreal Aflibercept Treatment on Exudative Age-related Macular Degeneration Patients

Not Applicable

Completed

• Conditions: Exudative age-related macular degeneration; Eye - Diseases / disorders of the eye

• Registration Number: ACTRN12612001310853
• Lead Sponsor: Sydney Retina Clinic and Day Surgery

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-12-18
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1) Previously or currently being treated with, or initiating treatment, with aflibercept for exudative AMD; and
2) Ability to provide informed consent and complete study assessments

Exclusion Criteria

Pregnancy or lactation
Premenopausal women not using contraception
Prior anti-VEGF injection in the study eye within 28 days of baseline
Prior treatment with photo dynamic therapy (PDT) within 90 days of baseline and more than 6 prior PDT treatments
Significant subretinal fibrosis or atrophy
Prior treatment with triamcinolone in the study eye within 6 months of baseline
Intraocular surgery in the study eye within 2 months of baseline
Simultaneous participation in a study that includes administration of any investigational drug or procedures.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Best-corrected visual acuity will be tested by snellen visual acuity chart or Early Treatment Diabetic Retinopathy Study (ETDRS) eye Charts. The patients will be asked to read letters from the top of the chart to the bottom, and the visual acuity is scored by how many letters could be correctly identified.[2 year];Macular thickness will be measured by optical coherence tomography[2 year]

Secondary Outcome Measures

Name	Time	Method
All adverse events,including study treatment related (Including eye pain, floater, irritation and haemorrhage, etc.) or unrelated (including stroke, heart attack and pneumonia, etc), will be recorded during the 24 months’ follow up.[2 years]